186 related articles for article (PubMed ID: 15609318)
1. Farnesyltransferase inhibitor SCH-66336 downregulates secretion of matrix proteinases and inhibits carcinoma cell migration.
Desrosiers RR; Cusson MH; Turcotte S; Béliveau R
Int J Cancer; 2005 May; 114(5):702-12. PubMed ID: 15609318
[TBL] [Abstract][Full Text] [Related]
2. Protein farnesyltransferase inhibitor (SCH 66336) abolishes NF-kappaB activation induced by various carcinogens and inflammatory stimuli leading to suppression of NF-kappaB-regulated gene expression and up-regulation of apoptosis.
Takada Y; Khuri FR; Aggarwal BB
J Biol Chem; 2004 Jun; 279(25):26287-99. PubMed ID: 15090542
[TBL] [Abstract][Full Text] [Related]
3. Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer.
Kim TD; Song KS; Li G; Choi H; Park HD; Lim K; Hwang BD; Yoon WH
BMC Cancer; 2006 Aug; 6():211. PubMed ID: 16916471
[TBL] [Abstract][Full Text] [Related]
4. The p75(NTR) metastasis suppressor inhibits urokinase plasminogen activator, matrix metalloproteinase-2 and matrix metalloproteinase-9 in PC-3 prostate cancer cells.
Nalbandian A; Djakiew D
Clin Exp Metastasis; 2006; 23(2):107-16. PubMed ID: 16912916
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the invasion-metastasis mechanism in pancreatic cancer: involvement of plasmin(ogen) cascade proteins in the invasion of pancreatic cancer cells.
Tan X; Egami H; Nozawa F; Abe M; Baba H
Int J Oncol; 2006 Feb; 28(2):369-74. PubMed ID: 16391791
[TBL] [Abstract][Full Text] [Related]
6. Induction of the plasminogen activator system by mechanical stimulation of human bronchial epithelial cells.
Chu EK; Cheng J; Foley JS; Mecham BH; Owen CA; Haley KJ; Mariani TJ; Kohane IS; Tschumperlin DJ; Drazen JM
Am J Respir Cell Mol Biol; 2006 Dec; 35(6):628-38. PubMed ID: 16794260
[TBL] [Abstract][Full Text] [Related]
7. Effects of SCH 59228, an orally bioavailable farnesyl protein transferase inhibitor, on the growth of oncogene-transformed fibroblasts and a human colon carcinoma xenograft in nude mice.
Liu M; Bryant MS; Chen J; Lee S; Yaremko B; Li Z; Dell J; Lipari P; Malkowski M; Prioli N; Rossman RR; Korfmacher WA; Nomeir AA; Lin CC; Mallams AK; Doll RJ; Catino JJ; Girijavallabhan VM; Kirschmeier P; Bishop WR
Cancer Chemother Pharmacol; 1999; 43(1):50-8. PubMed ID: 9923541
[TBL] [Abstract][Full Text] [Related]
8. Transforming growth factor-beta1 inhibits tumor growth in a mouse melanoma model by down-regulating the plasminogen activation system.
Ramont L; Pasco S; Hornebeck W; Maquart FX; Monboisse JC
Exp Cell Res; 2003 Nov; 291(1):1-10. PubMed ID: 14597403
[TBL] [Abstract][Full Text] [Related]
9. Down-regulation of urokinase plasminogen activator and matrix metalloproteinases and up-regulation of their inhibitors by a novel nutrient mixture in human prostate cancer cell lines PC-3 and DU-145.
Roomi MW; Kalinovsky T; Rath M; Niedzwiecki A
Oncol Rep; 2011 Dec; 26(6):1407-13. PubMed ID: 21874261
[TBL] [Abstract][Full Text] [Related]
10. Fibronectin upregulates gelatinase B (MMP-9) and induces coordinated expression of gelatinase A (MMP-2) and its activator MT1-MMP (MMP-14) by human T lymphocyte cell lines. A process repressed through RAS/MAP kinase signaling pathways.
Esparza J; Vilardell C; Calvo J; Juan M; Vives J; Urbano-Márquez A; Yagüe J; Cid MC
Blood; 1999 Oct; 94(8):2754-66. PubMed ID: 10515879
[TBL] [Abstract][Full Text] [Related]
11. Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants.
Mazzieri R; Masiero L; Zanetta L; Monea S; Onisto M; Garbisa S; Mignatti P
EMBO J; 1997 May; 16(9):2319-32. PubMed ID: 9171346
[TBL] [Abstract][Full Text] [Related]
12. The farnesyl transferase inhibitor SCH 66336 induces a G(2) --> M or G(1) pause in sensitive human tumor cell lines.
Ashar HR; James L; Gray K; Carr D; McGuirk M; Maxwell E; Black S; Armstrong L; Doll RJ; Taveras AG; Bishop WR; Kirschmeier P
Exp Cell Res; 2001 Jan; 262(1):17-27. PubMed ID: 11120601
[TBL] [Abstract][Full Text] [Related]
13. In vitro study of farnesyltransferase inhibitor SCH 66336, in combination with chemotherapy and radiation, in non-small cell lung cancer cell lines.
Loprevite M; Favoni RE; De Cupis A; Scolaro T; Semino C; Mazzanti P; Ardizzoni A
Oncol Rep; 2004 Feb; 11(2):407-14. PubMed ID: 14719076
[TBL] [Abstract][Full Text] [Related]
14. Interaction between cancer cells and stromal fibroblasts is required for activation of the uPAR-uPA-MMP-2 cascade in pancreatic cancer metastasis.
He Y; Liu XD; Chen ZY; Zhu J; Xiong Y; Li K; Dong JH; Li X
Clin Cancer Res; 2007 Jun; 13(11):3115-24. PubMed ID: 17545513
[TBL] [Abstract][Full Text] [Related]
15. RNAi-mediated downregulation of urokinase plasminogen activator receptor and matrix metalloprotease-9 in human breast cancer cells results in decreased tumor invasion, angiogenesis and growth.
Kunigal S; Lakka SS; Gondi CS; Estes N; Rao JS
Int J Cancer; 2007 Nov; 121(10):2307-16. PubMed ID: 17657740
[TBL] [Abstract][Full Text] [Related]
16. JNK suppression is essential for 17β-Estradiol inhibits prostaglandin E2-Induced uPA and MMP-9 expressions and cell migration in human LoVo colon cancer cells.
Hsu HH; Hu WS; Lin YM; Kuo WW; Chen LM; Chen WK; Hwang JM; Tsai FJ; Liu CJ; Huang CY
J Biomed Sci; 2011 Aug; 18(1):61. PubMed ID: 21859479
[TBL] [Abstract][Full Text] [Related]
17. Exploitation of astrocytes by glioma cells to facilitate invasiveness: a mechanism involving matrix metalloproteinase-2 and the urokinase-type plasminogen activator-plasmin cascade.
Le DM; Besson A; Fogg DK; Choi KS; Waisman DM; Goodyer CG; Rewcastle B; Yong VW
J Neurosci; 2003 May; 23(10):4034-43. PubMed ID: 12764090
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-1alpha enhances the aggressive behavior of pancreatic cancer cells by regulating the alpha6beta1-integrin and urokinase plasminogen activator receptor expression.
Sawai H; Okada Y; Funahashi H; Matsuo Y; Takahashi H; Takeyama H; Manabe T
BMC Cell Biol; 2006 Feb; 7():8. PubMed ID: 16504015
[TBL] [Abstract][Full Text] [Related]
19. Macrophages of M1 phenotype have properties that influence lung cancer cell progression.
Hedbrant A; Wijkander J; Seidal T; Delbro D; Erlandsson A
Tumour Biol; 2015 Nov; 36(11):8715-25. PubMed ID: 26050228
[TBL] [Abstract][Full Text] [Related]
20. Gallic acid suppresses the migration and invasion of PC-3 human prostate cancer cells via inhibition of matrix metalloproteinase-2 and -9 signaling pathways.
Liu KC; Huang AC; Wu PP; Lin HY; Chueh FS; Yang JS; Lu CC; Chiang JH; Meng M; Chung JG
Oncol Rep; 2011 Jul; 26(1):177-84. PubMed ID: 21503582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
